Larazotide
Also referred to as: Larazotide acetate, AT-1001
A peptide studied for tightening the gut barrier, researched mainly in celiac disease — one of the more clinically studied gut peptides.
In plain terms: Larazotide is a peptide studied for tightening up the "seams" between cells in the gut lining, so less leaks through. Most of the research is in celiac disease, and it has been tested fairly seriously in people — though it is not approved.
- Name
- Larazotide
- Aliases
- Larazotide acetate, AT-1001
- Classification
- Gut-barrier peptide
- Areas studied
- Gut barrier, Celiac research, Tight junctions
What it is
Larazotide is a lab-made peptide studied for its effect on the gut barrier — the lining that controls what passes from the intestine into the body. It is designed to act only inside the gut rather than being absorbed.
It has one of the more substantial human research records among gut peptides, mostly in celiac disease.
Mechanism
The gut lining has microscopic "seams" between its cells called tight junctions. When these loosen, more can pass through (sometimes called a "leaky" gut). Larazotide is studied for helping keep these seams tight, reducing what gets through.
This has been studied in cell, animal, and human research focused on celiac disease.
Areas studied & investigated
The categories below summarize where Larazotide appears in the research literature. They describe what the compound is studied for and investigated in — not approved uses, and not guidance for any kind of use.
Gut barrier
Studied for tightening the seams between cells in the gut lining.
Celiac research
The main focus, studied as a possible add-on to a gluten-free diet.
Tight junctions
A research example of targeting the cell-to-cell seams in the gut.
Gut-only action
Designed to work locally in the gut rather than being absorbed.
Research history
Larazotide came out of research into the gut barrier and the protein zonulin. It progressed through human clinical trials for celiac disease in the 2010s, with results in major gastroenterology journals.
State of the literature
Larazotide has been studied in registered human trials for celiac disease, with mixed late-stage results. It is not an approved drug. Research continues.
What to keep in mind
Larazotide has more human data than most gut peptides, but its late-stage celiac trials did not clearly succeed — a reminder that even well-studied compounds often do not pan out. "Studied for leaky gut" is also a phrase marketing loves; the actual research is specific to celiac disease, not a general gut fix. Read the trial results, not the slogans.
Research tools
Evaluating a Larazotide batch for laboratory research? These free, research-use-only calculators help you work the numbers and read the paperwork: the reconstitution calculator solves vial concentration and draw volume, and the COA reader walks a certificate line by line. For how much and how often Larazotide is commonly used, see the dosing guides.
Batch-tested with published COAs
See what a published COA looks like
Midwest Compounds does not currently list Larazotide. Every compound it does sell is tested by an independent lab, with a batch-linked certificate of analysis you can check before you buy.
Citations
The summary above is drawn from published, peer-reviewed sources. Links open the abstract on PubMed, or the free full text on PubMed Central (PMC) where marked.
- Leffler DA, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology, 2015. Abstract
- Khaleghi S, et al. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therapeutic Advances in Gastroenterology, 2016. Abstract